ANNUAL REPORT 2013

FINANCIALS

CONSOLIDATED FINANCIAL STATEMENTS, IFRS



Consolidated income statement


EUR million Note 2013
2012
Net sales 2 798.6
747.8
Cost of goods sold 6 -475.3
-473.2
Gross profit
323.2 40% 274.6 37%









Other operating income 5 3.1
2.1
Sales and marketing expenses 6 -164.7
-128.9
Administration expenses 6 -82.0
-73.5
Research and development costs 6 -13.3
-10.3
Other operating expenses 6 -1.5
-0.1
Goodwill impairment 6 -3.7


Operating profit (EBIT)
61.0 8% 63.9 9%









Change in fair value of biological assets 13 0.7
5.6
Share of profit from associate 15 50.8
47.8
Gain on sale of associate shares 15

87.0
Other financial income and expenses 8 -4.3
-3.8
Profit before taxes
108.3 14% 200.4 27%









Income taxes 9 -14.3
-21.5









Profit for the period
94.0 12% 178.9 24%









Attributable to:





Equity holders of the parent company
93.7
178.9

Non-controlling interest
0.3











Earnings for equity holders of the parent company
per share, euro (basic and diluted)
10 1.14
2.18

Consolidated statement of comprehensive income


EUR million Note 2013
2012
Profit for the period
94.0
178.9
Other comprehensive income for the period:





Items that may be reclassified subsequently to profit or loss:






Translation differences
-8.5
-1.0


Change in associate recognized directly in other
comprehensive income
15 -13.9
0.3



transferred to income statement


-0.1


Cash flow hedges
0.5
-0.8

Items that will not be reclassified to profit or loss:






Defined benefit plan, actuarial gains (losses),
net of tax
21 -0.2
-0.5


Change in associate recognized directly in other
comprehensive income
15 -5.6


Other comprehensive income for the period, net of tax
-27.7
-2.2









Total comprehensive income for the period
66.3
176.7









Attributable to:





Equity holders of the parent company
66.1
176.7

Non-controlling interest
0.2











The notes are an integral part of these consolidated financial statements.